Coya Therapeutics to Participate at the LifeSci Partners Summer Symposium

HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, will provide a corporate update at the LifeSci Partners Summer Symposium on Wednesday, July 21, 2021, at 10:30 a.m. ET.

To register in advance for the presentation, please click here. The presentation and archived webcast will also be accessible under “Events” in the news section of Coya website

About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics (TM) is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company’s CTreg (TM) (Cryopreservation for Tregs) system is patent pending and the first in the industry to overcome prior limitations of Treg cell therapies, allowing for serial infusions from a single manufacturing round. Through our proprietary TAI™ (Tregs Against Inflammation™) and patent pending iscEXO (TM) (immunosuppressive cell Exosome) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Frontotemporal Dementia, Parkinson’s, Alzheimer’s, and autoimmune diseases. For more information, please visit www.coyatherapeutics.com

Investor Contact
Daniel Ferry
617-430-7576
Daniel@lifesciadvisors.com

Media Contact
Jessica Starman
media@coyatherapeutics.com


Primary Logo

Back to news